Since we have demonstrated that Flcn deficiency leads to the activation of the mTOR pathway in those kidney cysts [31], we expected that mTOR was also activated in these high-grade allograft RCCs originated from the cystic hyperplasia/micro-tumor cells. This evidence concerns the gene FLCN and neoplasm.